Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib, Letrozole, and Anlotinib Neoadjuvant Therapy in HR+/HER2- Breast Cancer
NCT06605690Not yet recruiting
- Start
- Oct 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of dalpiciclib and anlotinib in breast cancer. Primary endpoint: Objective Response Rate at 24 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
dalpiciclibanlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06605690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06605690.